Optum Specialty Pharmacy Competitors and Similar CompaniesClear all
Optum Specialty Pharmacy's competitors and similar companies include U.S. Physical Therapy, Somatus and CorMedix.
 Optum Specialty Pharmacy Optum Specialty Pharmacy (formerly known as BriovaRx and AxelaCare) is a provider of home infusion services. |  U.S. Physical Therapy U.S. Physical Therapy is a company that operates physical and occupational therapy clinics in over 40 states. |  CorMedix CorMedix is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney disease. | ||
Founding Date | Founding Date 2008 | Founding Date 1990 | Founding Date 2016 | Founding Date 2006 |
Type | Type Subsidiary | Type Public | Type Private | Type Public |
Tags | ||||
Locations | Locations Eden Prairie, US HQ | Locations Houston, US HQ | Locations McLean, US HQ | Locations Berkeley Heights, US HQ |
Employees | Employees 831% decrease | Employees 3,1003% increase | Employees 768 | Employees 3036% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) N/A | Valuation ($) 749.2 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $781m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $311.7m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $149.7m (FY, 2025) | Gross profit N/A | Gross profit $275.7m (FY, 2025) |
Net income | Net income N/A | Net income $58m (FY, 2025) | Net income N/A | Net income $163.1m (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised $ 66m | Total funding raised N/A | Total funding raised $ 80m | Total funding raised $ 11.5m |
For sources of this data, please see the company profile
View Company Profiles
U.S. Physical Therapy
HQ
Houston, US
Employees
3,100↑ 3% increase
U.S. Physical Therapy is a company that operates physical and occupational therapy clinics in over 40 states.
View companyCorMedix
HQ
Berkeley Heights, US
Employees
30↑ 36% increase
CorMedix is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney disease.
View company